Category Archives: Events
By Michael Christel | Published: July 7, 2014
The Physicians Payment Sunshine Act, more formally referred to as Open Payments, has been in place for almost 18 months. It is only in the next few months, however, that the implications of the law and its contentious requirements will start to be fully realised. Michael Christel reports.
By William Looney | Published: July 1, 2014
Is the FDA doing enough to incorporate the patient perspective in the drug review process? This was the key question considered at a panel of regulatory experts held at last month’s annual BIO International Convention in San Diego. The consensus: while FDA deserves high marks for effort, both in reconciling the diversity of patient organization […]
By Guest Blogger | Published: June 30, 2014
The Drug Information Association (DIA), one of the largest non-profit organizations supporting clinical research and drug development, held its 2014 annual meeting in San Diego last week. Applied Clinical Trials’ Moe Alsumidaie looks at three of the key themes from this year’s meeting: incorporating advocacy groups and patient voices in clinical research, breakthrough research applications, and […]
By Julian Upton | Published: June 19, 2014
The UK government pledged late last year that it would double funding for dementia research by 2025 (from £66m [US$112m] in 2015 to £122m [US$207m]), but today Prime Minister David Cameron spoke on the subject again in light of expert warnings that little progress is being made. At the first legacy event of the G8 […]
By Pharm Exec | Published: June 17, 2014
A new report from GlobalData states that the increase of biosimilars will have a negative impact on the biologics market after 2019. The report cites patent expirations of branded biologics and regulatory clarification as reasons for the prediction that biosimilars will capture the market share after 2019.